Cancer patients get continued access to targeted therapy in safety Follow-Up

NCT ID NCT03340506

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Sep 30, 2025 · Last updated May 12, 2026 · Updated 28 times

Summary

This study offers continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were already benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to monitor long-term safety and side effects over time. Participants must have completed the earlier study and be judged by their doctor as likely to benefit from ongoing treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Honor Health Research Institute
ACTIVE_NOT_RECRUITING

Scottsdale, Arizona, 85258, United States
Honor Health Research Institute
RECRUITING

Scottsdale, Arizona, 85258, United States

Contact
James Cancer Hospital and Solove Research Institute Ohio State
COMPLETED

Columbus, Ohio, 43210, United States
Mary Crowley Cancer Research
COMPLETED

Dallas, Texas, 75251, United States
National Institute Of Health
ACTIVE_NOT_RECRUITING

Bethesda, Maryland, 20892, United States
Novartis Investigative Site
COMPLETED

Caba, Buenos Aires, C1121ABE, Argentina
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Innsbruck, Tyrol, 6020, Austria
Novartis Investigative Site
COMPLETED

Beijing, 100036, China
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Copenhagen, DK-2100, Denmark
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Lyon, 69373, France
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Nantes, 44093, France
Novartis Investigative Site
COMPLETED

Paris, 75970, France
Novartis Investigative Site
COMPLETED

Villejuif, 94800, France
Novartis Investigative Site
COMPLETED

Mannheim, Baden-Wurttemberg, 68305, Germany
Novartis Investigative Site
COMPLETED

Berlin, 13353, Germany
Novartis Investigative Site
COMPLETED

Hamburg, 20246, Germany
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Heidelberg, 69120, Germany
Novartis Investigative Site
COMPLETED

Debrecen, Hajdu Bihar Megye, 4032, Hungary
Novartis Investigative Site
COMPLETED

Budapest, H 1122, Hungary
Novartis Investigative Site
COMPLETED

Kashiwa, Chiba, 277-8577, Japan
Novartis Investigative Site
COMPLETED

Chuo Ku, Tokyo, 1040045, Japan
Novartis Investigative Site
COMPLETED

Rotterdam, South Holland, 3015 GD, Netherlands
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Utrecht, 3584 CX, Netherlands
Novartis Investigative Site
RECRUITING

Barcelona, 08035, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28040, Spain
Novartis Investigative Site
COMPLETED

Madrid, 28041, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28050, Spain
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Songkhla, Hat Yai, 90110, Thailand

Conditions

Explore the condition pages connected to this study.

HIGH GRADE GLIOMA MELANOMA NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER RARE CANCERS SOLID TUMOR